Atara Biotherapeutics (ATRA) EBITDA Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly EBITDA Margin came in at 749.21% in Q2 2026, down 76740.0% on a YoY basis from N/an in Q2 2025, and down 14.75% quarter-over-quarter from 652.91% in Q1 2026.
Powered by 
Analysis
Atara Biotherapeutics (ATRA) EBITDA Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has reported EBITDA Margin for 6 consecutive years, with 749.21% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 76740.0% year-over-year to 749.21%; the trailing twelve-month figure through Jun 2026 stood at 229.67% (down 23393.0% YoY), and the FY2025 full-year result was 29.69%, up 9440.0% from the prior year.
- EBITDA Margin declined to 749.21% in Q2 2026 per ATRA's latest filing, from 652.91% in the prior quarter.
- Across five years, EBITDA Margin topped out at 39.53% in Q1 2025 and bottomed at 30459.27% in Q4 2022.
- Historically, EBITDA Margin has averaged 2986.15% across 5 years, with a median of 406.8% in 2025.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin slumped 2922182 bps in 2022, then jumped 2904907 bps in 2023.
- Over 5 years, EBITDA Margin stood at 30459.27% in 2022, then jumped by 95 bps to 1410.21% in 2023, then surged by 97 bps to 37.26% in 2024, then sank by 331 bps to 160.69% in 2025, then slumped by 366 bps to 749.21% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 749.21%, 652.91%, and 160.69% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | -25,827.14% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 0.56% |
| 10 | Atara Biotherapeutics | 148.00 Mn | 131.45 Mn | 439,000.00 | -749.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -749.21% |
| Mar 31, 2026 | -652.91% |
| Dec 31, 2025 | -160.69% |
| Sep 30, 2025 | -103.50% |
| Jun 30, 2025 | 18.19% |
| Mar 31, 2025 | 39.53% |
| Dec 31, 2024 | -37.26% |
| Sep 30, 2024 | -54.14% |
| Jun 30, 2024 | -63.66% |
| Mar 31, 2024 | -114.22% |
| Dec 31, 2023 | -1,410.21% |
| Sep 30, 2023 | -3,255.94% |
| Jun 30, 2023 | -7,462.28% |
| Mar 31, 2023 | -6,118.92% |
| Dec 31, 2022 | -30,459.27% |
| Sep 30, 2022 | -1,897.78% |
| Jun 30, 2022 | -62.30% |
| Mar 31, 2022 | -1,206.18% |
| Dec 31, 2021 | -1,237.45% |
| Sep 30, 2021 | -1,579.37% |